Allarity Therapeutics, INC. (ALLR) — SEC Filings

Overview

Allarity Therapeutics, INC. (ALLR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3/A filed on Apr 24, 2026: Allarity Therapeutics, Inc. filed an amendment (S-3/A) on April 24, 2026, to its registration statement. This filing includes an amendment to the S-3 and a consent from their independent registered public accounting firm, Wolf & Company, P.C. The company is located at 24 School St., 2nd Floor, Bosto

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Allarity Therapeutics, INC. is neutral.

Filing Type Overview

Allarity Therapeutics, INC. (ALLR) has filed 1 S-3/A, 37 8-K, 5 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G/A, 1 8-K/A, 1 SC 13G, 1 DEFA14A with the SEC between Jul 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Allarity Therapeutics Files S-3/A Amendment — S-3/A · Apr 24, 2026 Risk: medium
  Allarity Therapeutics, Inc. filed an amendment (S-3/A) on April 24, 2026, to its registration statement. This filing includes an amendment to the S-3 and a cons
• 8-K Filing — 8-K · Apr 22, 2026
• 8-K Filing — 8-K · Apr 1, 2026
• Allarity Therapeutics Reports Unregistered Equity Sales — 8-K · Dec 23, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on December 23, 2025, reporting unregistered sales of equity securities. The filing does not specify the number of shar
• Allarity Therapeutics Files 8-K on Officer/Director Changes — 8-K · Dec 8, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting events as of December 3, 2025. The filing indicates changes related to directors and off
• Allarity Narrows Losses, Boosts R&D Amid Cash Burn Concerns — 10-Q · Nov 14, 2025 Risk: high
  Allarity Therapeutics, Inc. reported a net loss of $2.8 million for the three months ended September 30, 2025, a significant improvement from the $11.59 million
• Allarity Therapeutics Files 8-K — 8-K · Sep 24, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on September 24, 2025, reporting an event on September 22, 2025. The filing indicates "Other Events" and "Financial Sta
• Allarity Therapeutics Files 8-K — 8-K · Sep 22, 2025 Risk: low
  On September 17, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial sta
• Allarity Therapeutics Files 8-K — 8-K · Aug 27, 2025 Risk: low
  On August 26, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
• Allarity Therapeutics Q2 2025: Assets $17M, Net Loss $2.4M — 10-Q · Aug 15, 2025 Risk: medium
  Allarity Therapeutics, Inc. reported its Q2 2025 financial results for the period ending June 30, 2025. The company had total assets of $17,075,338 and total li
• Allarity Therapeutics Files 8-K — 8-K · Jul 16, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princ
• Allarity Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jul 7, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on July 7, 2025, reporting events as of June 30, 2025. The filing primarily concerns the departure of directors, electi
• Allarity Therapeutics Files 8-K — 8-K · Jul 1, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on July 1, 2025, reporting events as of June 30, 2025. The filing primarily concerns other events and financial stateme
• Allarity Therapeutics Files 8-K Current Report — 8-K · Jun 30, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting an event that occurred on June 27, 2025. The filing indicates the company is incorporated i
• Allarity Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 17, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting on a submission of matters to a vote of security holders as of June 13, 2025. The company,
• Allarity Therapeutics Changes HQ, Reports Officer/Director Updates — 8-K · Jun 11, 2025 Risk: medium
  Allarity Therapeutics, Inc. announced on June 5, 2025, a change in its principal executive offices to 123 E Tarpon Ave, Tarpon Springs, FL 34689. The company al
• Allarity Therapeutics Files 8-K — 8-K · Jun 5, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting an event that occurred on June 4, 2025. The filing is categorized under 'Other Events' and '
• Allarity Therapeutics Files 8-K — 8-K · Jun 3, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The filing date for the report is June 2, 2025. The c
• Allarity Therapeutics Files 8-K — 8-K · May 13, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princi
• Allarity Therapeutics Q1 2025: Minimal Revenue, Assets $17M — 10-Q · May 9, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.000
• Allarity Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Allarity Therapeutics, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting of stockholders on June 13, 2025. The filing covers t
• Allarity Therapeutics Files 8-K — 8-K · Apr 28, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on April 28, 2025, reporting events as of April 25, 2025. The filing primarily concerns financial statements and exhibi
• Allarity Therapeutics Files 8-K on Director Changes — 8-K · Apr 16, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on April 16, 2025, reporting changes in its board of directors and compensatory arrangements. The filing also addresses
• Allarity Therapeutics Files 2024 10-K: Net Loss of $200K — 10-K · Mar 31, 2025 Risk: high
  Allarity Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $7.3 million and total liabilities
• Allarity Therapeutics Files 8-K — 8-K · Mar 25, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its prin
• Allarity Therapeutics Files 8-K — 8-K · Mar 18, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on March 18, 2025, reporting other events and financial statements. The filing details the company's principal executiv
• Allarity Therapeutics Files 8-K — 8-K · Mar 14, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on events that occurred on March 13, 2025. The filing primarily concerns financial stateme
• Allarity Therapeutics Files 8-K — 8-K · Mar 7, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting an "Other Events" and "Financial Statements and Exhibits" filing as of March 6, 2025. The c
• Allarity Therapeutics Files 8-K — 8-K · Mar 4, 2025 Risk: low
  On March 3, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 24 School Stree
• Allarity Therapeutics Files 8-K — 8-K · Feb 27, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting an event on February 26, 2025. The filing is primarily for "Other Events" and "Financia
• Allarity Therapeutics Files 8-K — 8-K · Feb 25, 2025 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting an event that occurred on February 24, 2025. The filing indicates "Other Events" and "F
• Allarity Therapeutics Files 8-K — 8-K · Feb 7, 2025 Risk: low
  On February 6, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• Allarity Therapeutics Files 8-K Report — 8-K · Jan 30, 2025 Risk: low
  On January 30, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific financial transa
• Allarity Therapeutics Files 8-K — 8-K · Nov 19, 2024 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The filing does not contain specific financial f
• Allarity Therapeutics Q3 2024: Minimal Revenue, High Expenses — 10-Q · Nov 14, 2024 Risk: high
  Allarity Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue, with $0.0001 for the three months end
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• Allarity Therapeutics Files 8-K — 8-K · Oct 23, 2024 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on October 23, 2024, reporting on events as of October 22, 2024. The filing primarily concerns financial statements and
• Allarity Therapeutics Files 8-K — 8-K · Oct 11, 2024 Risk: low
  On October 9, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
• Allarity Therapeutics Announces Executive and Board Changes — 8-K · Oct 4, 2024 Risk: medium
  On September 30, 2024, Allarity Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The company also anno
• Allarity Therapeutics Files 8-K — 8-K · Sep 17, 2024 Risk: low
  Allarity Therapeutics, Inc. filed an 8-K on September 17, 2024, reporting an event that occurred on September 16, 2024. The filing is categorized under Regulati
• Allarity Therapeutics Appoints New CMO, Adds Directors — 8-K · Sep 13, 2024 Risk: medium
  Allarity Therapeutics, Inc. announced on September 9, 2024, the appointment of Dr. Torbjörn Bjerke as Chief Medical Officer and the election of Dr. Bjerke and M
• Allarity Therapeutics Files 8-K Amendment — 8-K/A · Sep 10, 2024 Risk: medium
  Allarity Therapeutics, Inc. filed an amendment (No. 1) to its Form 8-K on September 10, 2024, reporting events that occurred on September 3, 2024. The amendment
• Allarity Therapeutics Reports Key Corporate Changes — 8-K · Sep 9, 2024 Risk: medium
  Allarity Therapeutics, Inc. filed an 8-K on September 9, 2024, reporting on several key events that occurred on September 3, 2024. These include material modifi
• SC 13G Filing — SC 13G · Aug 29, 2024
• Allarity Therapeutics Files 8-K: Material Agreements & Security Holder Changes — 8-K · Aug 21, 2024 Risk: medium
  Allarity Therapeutics, Inc. announced on August 19, 2024, that it entered into a material definitive agreement. The company also reported on material modificati
• Allarity Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 5, 2024 Risk: medium
  Allarity Therapeutics, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, is based in Boston, MA, and oper
• Allarity Therapeutics Files Proxy Statement Supplement — DEFA14A · Jul 26, 2024 Risk: low
  Allarity Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on July 26, 2024, for its 2024 Annual Meeting of Stockholders. The filing is
• Allarity Therapeutics Files 8-K Report — 8-K · Jul 23, 2024 Risk: low
  On July 22, 2024, Allarity Therapeutics, Inc. filed an 8-K report to disclose information regarding a Regulation FD disclosure and financial statements. The fil
• Allarity Therapeutics to be Acquired by 1450 LLC — 8-K · Jul 22, 2024 Risk: medium
  Allarity Therapeutics, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by 1450 LLC. The transaction is expected
• Allarity Therapeutics Files Proxy Statement for July 26 Meeting — DEF 14A · Jul 1, 2024 Risk: low
  Allarity Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on July 1, 2024, for its annual meeting of stockholders. The filing concerns the solici

Risk Profile

Risk Assessment: Of ALLR's 46 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Allarity Therapeutics, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$2.8M
• EPS: -$0.57
• Debt-to-Equity: 0.73
• Cash Position: $16.9M
• Operating Margin: N/A
• Total Assets: $20.8M
• Total Debt: $8.8M

Key Executives

• Dr. Anders M. Holmberg
• Dr. Steve R. Saklad
• Dr. Torbjörn Bjerke
• Ms. Ann-Christine Sundberg

Industry Context

Allarity Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Success hinges on innovative drug discovery, robust clinical trial execution, and the ability to secure substantial funding for research and development.

Top Tags

8-k (12) · filing (11) · sec-filing (9) · 8-K (6) · financials (6) · corporate-governance (5) · pharmaceuticals (4) · regulatory-filing (4) · 10-Q (4) · corporate-update (3)

Key Numbers

• Filing Date: 2026-04-24 — Date the S-3/A amendment was filed and accepted.
• Net Loss: $7.86M — for the nine months ended September 30, 2025, a decrease from $17.06M in 2024
• Cash and Cash Equivalents: $16.9M — as of September 30, 2025, down from $19.53M at December 31, 2024
• Net Cash Used in Operating Activities: $11.6M — for the nine months ended September 30, 2025, an improvement from $14.15M in 2024
• Accumulated Deficit: $126.8M — as of September 30, 2025, indicating significant historical losses
• Research and Development Expenses: $4.93M — for the nine months ended September 30, 2025, an increase from $4.25M in 2024
• General and Administrative Expenses: $4.76M — for the nine months ended September 30, 2025, a decrease from $5.97M in 2024
• Common Shares Outstanding: 15,811,886 — as of November 13, 2025
• Net Loss Per Common Share: $0.57 — for the nine months ended September 30, 2025, a significant improvement from $25.33 in 2024
• Total Assets: $17.08M — As of June 30, 2025, indicating the company's resources.
• Total Liabilities: $7.30M — As of June 30, 2025, representing the company's obligations.
• Total Equity: $9.77M — As of June 30, 2025, reflecting the net worth of the company.
• Net Loss (YTD): $2.46M — For the six months ended June 30, 2025, showing profitability.
• SEC File Number: 001-41160 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 87-2147982 — Company's tax identification number.

Frequently Asked Questions